Visualization of the thymus by substance P receptor scintigraphy in man
- PMID: 8854850
- DOI: 10.1007/BF01254476
Visualization of the thymus by substance P receptor scintigraphy in man
Abstract
Substance P, an 11-amino acid neuropeptide, has an important role in modulating pain transmission through neurokinin 1 and 2 receptors. Substance P and other tachykinins may also play a role in the pathogenesis of inflammatory diseases. In this study we present the results concerning the metabolism of the substance P analogue [111In-DTPA-Arg1]-substance P in man, as well as the visualization of the thymus in patients with immune-mediated diseases. Twelve selected patients were investigated, comprising five with inflammatory bowel disease, one with ophthalmic Graves' disease, one with sclerosing cholangitis, one with Sjögren's syndrome, one with rheumatoid arthritis, one with systemic lupus erythematosus and two with myasthenia gravis. During and after intravenous administration of 150-250 MBq (2.5-5.0 microg) [111In-DTPA-Arg1]-substance P, blood pressure, heart rate and oxygen saturation were monitored. Radioactivity was measured in blood, urine and faeces during the 48 h after injection. Planar and single-photon emission tomographic images were obtained 4 and 24 h after injection. After administration of [111In-DTPA-Arg1]-substance P, a transient flush was observed in all patients. Degradation of [111In-DTPA-Arg1]-substance P started in the first minutes after administration, resulting in a half-life of 10 min for the total plasma radioactivity, and of 4 min for the intact radiopharmaceutical, as identified with high-performance liquid chromatography. Urinary excretion accounted for >95% of the radioactivity within 24 h post injection, and up to 0.05% was found in the faeces up to 60 h. In all patients uptake of radioactivity was found in the areolae mammae (in women), liver, spleen, kidneys and urinary bladder. In eight patients a high uptake of [111In-DTPA-Arg1]-substance P was observed in the thymus. We conclude that, despite its short half-life, [111In-DTPA-Arg1]-substance P, a new radiopharmaceutical, can be used to visualize the thymus. This may contribute to the investigation of the role of thymus in immune-mediated diseases. In addition, inflammatory sites in various diseases could be visualized.
Similar articles
-
In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium-111-DTPA-Arg1]substance P.J Nucl Med. 1996 Jan;37(1):108-17. J Nucl Med. 1996. PMID: 8543978
-
Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.J Nucl Med. 1992 May;33(5):652-8. J Nucl Med. 1992. PMID: 1349039
-
Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.J Clin Endocrinol Metab. 1998 Nov;83(11):3790-4. doi: 10.1210/jcem.83.11.5274. J Clin Endocrinol Metab. 1998. PMID: 9814448 Clinical Trial.
-
111In-octreotide scintigraphy in oncology.Metabolism. 1992 Sep;41(9 Suppl 2):83-6. doi: 10.1016/0026-0495(92)90038-c. Metabolism. 1992. PMID: 1355591 Review.
-
Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.Eur J Nucl Med. 1993 Aug;20(8):716-31. doi: 10.1007/BF00181765. Eur J Nucl Med. 1993. PMID: 8404961 Review.
Cited by
-
The 68Ge/ 68Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine?Eur J Nucl Med Mol Imaging. 2007 Jul;34(7):978-81. doi: 10.1007/s00259-007-0387-4. Eur J Nucl Med Mol Imaging. 2007. PMID: 17333177 Free PMC article. No abstract available.
-
Nuclear medicine imaging and therapy of neuroendocrine tumours.Cancer Imaging. 2006 Oct 31;6(Spec No A):S178-84. doi: 10.1102/1470-7330.2006.9038. Cancer Imaging. 2006. PMID: 17114073 Free PMC article.
-
Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002.Eur J Nucl Med Mol Imaging. 2003 Mar;30(3):463-9. doi: 10.1007/s00259-002-1107-8. Epub 2003 Feb 5. Eur J Nucl Med Mol Imaging. 2003. PMID: 12569416 Review.
-
A novel gallium bisaminothiolate complex as a myocardial perfusion imaging agent.Nucl Med Biol. 2008 Jan;35(1):83-90. doi: 10.1016/j.nucmedbio.2007.08.002. Epub 2007 Nov 19. Nucl Med Biol. 2008. PMID: 18158947 Free PMC article.
-
What can gallium-68 PET add to receptor and molecular imaging?Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):1897-901. doi: 10.1007/s00259-007-0568-1. Eur J Nucl Med Mol Imaging. 2007. PMID: 17713764 No abstract available.
References
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous